1.Research on classification of prescriptions in Treatment Record of Hundreds of Selected Ancient Prescriptions based on hierarchical clustering
Tao FENG ; Zhijie DU ; Yuefen YU ; Wei WANG
International Journal of Traditional Chinese Medicine 2021;43(1):68-71
Objective:Based on systematic idea of clustering methods, a novel approach for classifying prescriptions was explored in the light of the method of classifying analogous prescriptions.Methods:A total of 581 ancient prescriptions were selected from Treatment Record of Hundreds of Selected Ancient Prescriptions, and the standardized names of Traditional Chinese Medicines in these prescriptions were entered in Microsoft Excel 2007, then imported to SPSS 24.0 to generate dendrograms using the hierarchical clustering function. The classification of 581 selected ancient prescriptions was analyzed. Results:All 581 prescriptions could be classified into 86 categories through repeated clustering, the largest group has 29 prescriptions, the smallest group has 2 prescriptions, and the average group has about 6.75 prescriptions. In general, the later the intercepted group, the lower the similarity of its internal prescriptions.Conclusion:This method could realize the classification of prescriptions in the light of the method of classifying analogous prescriptions, which may help to break the original thinking bondage and further deepen the understanding of compatibility rules of prescriptions. However, its disadvantage lied in that the theoretical clues would be reduced when analyzing the compatibility rules of prescriptions and the issues of drug dosage, nature, taste and meridian categories were not specially considered.
2.The value of serum microRNA-92a and microRNA-146a levels combined with pulmonary ultrasound score in predicting the severity and prognosis of acute respiratory distress syndrome
Yuefen YU ; Zhenhua LIU ; Haiyan LIAO ; Yanlian HE ; Caizhong LI
Chinese Critical Care Medicine 2020;32(10):1231-1235
Objective:To investigate the value of serum microRNA-92a (miR-92a) and microRNA-146a (miR-146a) expression levels combined with lung ultrasound score (LUS) in predicting the severity and prognosis of acute respiratory distress syndrome (ARDS).Methods:116 patients with ARDS admitted to Danzhou People's Hospital from January 2017 to March 2020 were enrolled. On the day of admission, the expression levels of serum miR-92a and miR-146a were detected by real-time fluorescent quantitative reverse transcript-polymerase chain reaction (RT-PCR), and pulmonary ultrasound examination was performed in 12 lung regions, with the total score as LUS score. The difference of each index was analyzed among the ARDS patients with different 28-day prognosis (survival group and death group) and different severity [mild group: 200 mmHg < oxygenation index (OI) ≤ 300 mmHg (1 mmHg = 0.133 kPa), moderate group: 100 mmHg < OI≤200 mmHg, severe group: OI≤100 mmHg]. Multivariate Logistic regression was used to analyze the risk factors of death in patients with ARDS. Receiver operating characteristic (ROC) curve was drawn to analyze the value of miR-92a and miR-146a combined with LUS score in predicting the death of patients with ARDS.Results:116 ARDS patients were included, 39 cases in the death group, 77 cases in the survival group; 20 cases in the mild group, 38 cases in the moderate group and 58 cases in the severe group. The expression levels of serum miR-92a, miR-146a and LUS score in the death group were significantly higher than those in the survival group [miR-92a (2 -ΔΔCt): 3.75±1.64 vs. 2.10±0.78, miR-146a (2 -ΔΔCt): 1.93±0.72 vs. 0.76±0.20, LUS score: 25.80±4.75 vs. 13.40±3.60, all P < 0.01]. With the aggravation of ARDS patients, the expression levels of serum miR-92a and miR-146a and LUS score gradually increased ( F values were 8.115, 6.740 and 6.216 respectively, all P < 0.01). The expression levels of serum miR-92a, miR-146a and LUS score in severe group were significantly higher than those in the moderate group and mild group [miR-92a (2 -ΔΔCt): 3.65±1.62 vs. 2.87±1.16, 1.94±0.68; miR-146a (2 -ΔΔCt): 1.85±0.58 vs. 1.30±0.51, 0.68±0.17; LUS score: 24.15±4.65 vs. 18.60±4.20, 12.20±3.15, all P < 0.01]. Multivariate Logistic regression analysis showed that low OI [odds ratio ( OR) = 2.748, 95% confidence interval (95% CI) was 1.913-6.225, P = 0.024], high LUS score ( OR = 1.685, 95% CI was 1.183-2.758, P = 0.016), high expression levels of serum miR-92a ( OR = 2.560, 95% CI was 1.806-5.627, P < 0.001) and miR-146a ( OR = 1.984, 95% CI was 1.375-3.816, P = 0.008) were independent risk factors for the death of ARDS patients. ROC curve analysis showed that the area under ROC curve (AUC) of patients with ARDS predicted by miR-92a and miR-146a combined with LUS score was significantly higher than that predicted by the three alone (0.918 vs. 0.842, 0.825, 0.807, all P < 0.01), and the sensitivity (94.0%) and specificity (85.2%) were higher. Conclusion:The expression levels of serum miR-92a, miR-146a and LUS score are related to the severity and prognosis of the patients with ARDS, and the combination of the three indicators has better value in predicting the prognosis of the patients with ARDS.
3.A cohort study on treatment of chronic kidney disease 3 with qi deficiency and dampness-heat typebyqing-budigui decoction
Yuan MENG ; Yuefen WANG ; Dong CHEN ; Yu WANG ; Wenjing ZHAO ; Binghou ZHANG ; Cuiyan LYU
The Journal of Practical Medicine 2017;33(20):3472-3476
Objective To evaluate the clinical effects of the treatment on chronic kidney disease 3 with dampness-heat type. Methods A retrospective cohort study recruited 103 patients with qi deficiency and dampness-heat type of CKD3. Among them,51 cases in the control group were treated with western medicine therapy. The 52 cases in the treatment group received Qingbudigui Decoction. SCr ,eGFR and 24hU-Prowere were observed after 12 months and 24 months for evaluating the clinical effects of Qingbudigui Decoction. Results After 12 and 24 months treatment,the treatment group had a significantly lower SCr and U-Pro(P < 0.01),but a higher eGFR (P<0.01,P<0.05). After 12 months and 24 months,there was no significant change in SCr,U-Pro or eGFR in the control group (P > 0.05). Conclusions Combination therapy of the Qingbudigui Decoction of the patients with qi deficiency and dampness-heat type of CKD3 could delay the kidney disease,which is superior to simple western medicine group. The mechanism may be related to the reduction of urinary protein excretion.